Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)

被引：0
|
作者：
Peer, Avivit
Ish-Shalom, Maya
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Pili, Roberto
Maimon, Natalie
Gottfried, Maya
Hayat, Henry
Kovel, Svetlana
Sella, Avishay
Neumann, Avivit
Boursi, Ben
Berger, Raanan
Carducci, Michael Anthony
Keizman, Daniel
机构：
[1] Rambam Hlth Care Campus, Haifa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Genitourinary Oncol Serv,Div Oncol, Kefar Sava, Israel
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[5] Wolfson Med Ctr, Dept Oncol, Holon, Israel
[6] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
[7] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[8] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[9] Chaim Sheba Med Ctr, Ramat Gan, Israel
[10] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[11] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[12] Sidney Kimmel Comprehens Canc, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4619
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
    Keizman, Daniel
    Ish-Shalom, Maya
    Taksey, Jason David
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Boursi, Ben
    Berger, Raanan
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Peer, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [2] Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma
    Keizman, Daniel
    Ish-Shalom, Maya
    Pili, Roberto
    Hammers, Hans
    Eisenberger, Mario A.
    Sinibaldi, Victoria
    Boursi, Ben
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Peer, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Berger, Raanan
    Carducci, Michael A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (07) : 1031 - 1037
  • [3] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    ONCOLOGIST, 2023, 28 : S5 - +
  • [5] Use of early tumor shrinkage as a response to VEGF inhibitors as a predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Gruenwald, Viktor
    Seidel, Christoph
    Fenner, Martin
    Woike, Michael
    Kalanovic, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib
    Pinto, Alvaro
    Garrido, Maria
    Cruz, Patricia
    Lopez, David
    Zambrana, Francisco
    Aguayo, Cristina
    Fellu, Jaime
    Espinosa, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
    Verzoni, Elena
    Iacovelli, Roberto
    Rizzo, Mimma
    Felici, Alessandra
    Cascinu, Stefano
    Di Lorenzo, Giuseppe
    Cerbone, Linda
    Ortega, Cinzia
    Masini, Cristina
    Giganti, Maria Olga
    Lorusso, Vito
    Messina, Caterina
    Atzori, Francesco
    De Vincenzo, Fabio
    Sacco, Cosimo
    Boccardo, Francesco
    Valduga, Francesco
    Massari, Francesco
    Tassi, Renato
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [8] Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
    Keizman, Daniel
    Gottfried, Maya
    Ish-Shalom, Maya
    Maimon, Natalie
    Peer, Avivit
    Neumann, Avivit
    Hammers, Hans
    Eisenberger, Mario A.
    Sinibaldi, Victoria
    Pili, Roberto
    Hayat, Henry
    Kovel, Svetlana
    Sella, Avishay
    Boursi, Ben
    Weitzen, Rony
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Carducci, Michael A.
    ONCOLOGIST, 2014, 19 (01): : 51 - 60
  • [9] RELATIONSHIP BETWEEN OVERALL RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) IN CLINICAL TRIALS OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
    Jen, M. H.
    Sonksen, M.
    Hess, L.
    Bian, F.
    VALUE IN HEALTH, 2023, 26 (06) : S44 - S44
  • [10] Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Choueiri, T. K.
    Hessel, C.
    Halabi, S.
    Sanford, B.
    Hahn, O.
    Michaelson, M. D.
    Walsh, M.
    Olencki, T.
    Picus, J.
    Small, E. J.
    Dakhil, S.
    Scheffold, C.
    George, D. J.
    Morris, M. J.
    ANNALS OF ONCOLOGY, 2017, 28
12345